Understanding Biomarker Testing
Biomarker testing can help doctors better understand certain cancers and identify treatments that may be more effective for specific patients.
Cancer treatment has become increasingly personalized. Biomarker and genomic testing are now important parts of modern cancer care, yet many patients leave appointments unsure what these tests mean or why they matter.
MyCancerPath helps patients and families better understand this rapidly evolving area of cancer medicine.
What is biomarker testing?
Biomarker testing looks for specific features inside cancer cells that may help guide treatment decisions.
These biomarkers may include:
- gene mutations
- protein expression
- genomic alterations
- molecular signals linked to how a cancer behaves or responds to treatment
In some cancers, biomarker testing can help identify:
- targeted therapies
- immunotherapy eligibility
- clinical trial opportunities
- additional treatment pathways
Not every cancer has actionable biomarkers, but for some patients, biomarker testing can meaningfully influence treatment discussions and care planning.
Why biomarker testing matters
Modern oncology is evolving rapidly. New biomarkers and targeted therapies continue to emerge across many cancer types.
National cancer guidelines increasingly recommend biomarker testing for eligible patients because it may help identify therapies more closely matched to the biology of a specific cancer.
Research has shown that many eligible cancer patients still do not receive complete biomarker testing before treatment begins.
Only about one-third of eligible advanced cancer patients receive comprehensive biomarker testing.
Across several cancer types, fewer than half of patients received biomarker testing before first-line therapy.
NCCN guidelines increasingly recommend broad molecular profiling for many advanced cancers.
Common types of cancer biomarker testing
Genomic testing
Looks for DNA mutations or alterations within cancer cells.
Protein testing
Measures proteins that may influence treatment response, such as PD-L1 expression.
Next-generation sequencing (NGS)
A broader form of testing that can evaluate many biomarkers simultaneously.
Liquid biopsy
A blood-based test that may help detect certain tumor-related genetic changes.
Questions patients often ask
The answers often depend on cancer type, stage, available therapies, current guidelines, and previous testing performed.
MyCancerPath helps patients better understand these conversations so they can feel more prepared when speaking with their medical teams.
How MyCancerPath helps patients understand biomarker testing
Biomarker reports and genomic testing results can be difficult to interpret without scientific background knowledge.
MyCancerPath helps patients and families:
- understand terminology
- organize testing information
- clarify key concepts
- prepare questions for physicians
- better understand what results may mean for treatment discussions
Our role is educational and supportive. We do not diagnose cancer or prescribe treatment. We help patients better understand complex information during difficult moments.
Cancer science is advancing quickly, but patients still need explanations that feel clear, understandable, and deeply human.
MyCancerPath exists to help bridge the gap between rapidly evolving cancer science and the very human need for clarity and support.
Better understanding starts with better guidance.
Reach out to learn how MyCancerPath helps patients and families better understand biomarker testing, diagnosis, and treatment pathways.